Search Bar & Filters
Found 1 Actively Recruiting clinical trials
Actively Recruiting
This research aims to compare two antibiotic treatment regimens for staphylococcal prosthetic valve endocarditis. It evaluates whether a regimen without rifampin is not worse than the standard rifampin-containing treatment concerning all-cause death within six months after starting treatment. The study is a phase 3, multicenter, randomized controlled trial addressing concerns about rifampins side effects and drug interactions in patients with prosthetic heart valves. Participants will be randomly assigned to receive either an antibiotic regimen without rifampin or one including rifampin at 900 mg daily, both following guidelines from the 2023 European Society of Cardiology and 2025 French recommendations. The rifampin-free group will have other antibiotics chosen by their doctors according to these guidelines. Treatment will follow the recommended protocols for infective endocarditis caused by staphylococcus on prosthetic valves. During the study, participants will be monitored for up to 12 months to assess outcomes such as mortality, relapse, microbiological failure, embolic events, valve surgery, adverse effects, hospital stay length, and treatment duration. The main focus is on death from any cause within six months. Assessments include clinical evaluations and tracking of hospital readmissions. Participants will provide informed consent and be insured under a health plan, with regular follow-ups including phone contacts and diaries to record information.